Hi Sen-Jam Community,

We’re excited to share an important milestone as we continue accelerating the path to commercialization for SJP-002C, our therapeutic targeting Upper Respiratory Infections, including COVID.

👉 We’ve officially engaged Destum Partners, a global life science advisory firm with $5B+ in deal experience, to lead our strategic partnering efforts. Their goal: secure a license, co-development, or M&A transaction that drives maximum value for Sen-Jam and our investors.

📈 Destum has valued SJP-002C at $196M, with the opportunity to expand into a $500M+ asset over the next 24–36 months.

📄 We’re proud to share our new non-confidential deck that’s being used in partner outreach. You can review that here.

🎙️ Join Us Live — Tomorrow @ 5PM ET

We’re hosting a live webinar with Destum Partners to discuss the partnering strategy, timelines, and what this means for you.

💡 Featuring:

• Gareth Lugg and Matt Vanderberg, Managing Directors at Destum
• Our CEO, Jim Iversen, and CCO, Jackie Iversen RPh MS with a live Q&A

🗓️ RSVP Now

⏳ 14 Days Left — Wefunder Closes April 7th!

We’re in the final stretch of our raise. If you’ve been thinking about increasing your investment — or joining our mission for the first time — this is your moment. Invest here.

💬 Want to talk 1:1 with Jim?

📅 Book a quick call

Let’s go out strong 💥

The future of inflammation care is being built — thanks to YOU.

Let's do this,

Jim